Xcout Intel
Duo Oncology Inc.
Duo Oncology Inc. is a United States-based company located in Pittsburgh, Pennsylvania, specializing in stroma-penetrating nanomedicine to improve cancer treatments.
Subscribe to see Duo Oncology Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Duo Oncology Inc. at a glance
Duo Oncology Inc. is a biotechnology company headquartered in United States. It has raised at least $26M across the 4 funding rounds on record. Its most recent funding round, Seed, raised $1.6M in June 2025. Xcout tracks 16 named people at Duo Oncology Inc., including SAM ROTHSTEIN (President and CEO).
Duo Oncology Inc. leadership
- SAM ROTHSTEINPresident and CEO
- Dr. Sam Rothstein, PhDCEO & Co-Founder
- Dr. Jing-Zhou Hou, MD, PhDCo-Founder
- Dr. Song Li, MD, PhDCo-Founder
- JINGJING SUNPromoter
- JING-ZHOU HOUExecutive Officer
10 more named people on record for Duo Oncology Inc., with roles, board committees and tenure — see the full roster →
Duo Oncology Inc. funding rounds
At least $26M raised across the 4 rounds on record. The 3 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $1.6M | 6 named | |
| Seed | $19M | 6 named | |
| SEC Form D filing | $4.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Duo Oncology Inc. competitors
A few of Duo Oncology Inc.'s closest competitors — see the full list of competitors and alternatives →
Western Oncolytics Ltd. is a cutting-edge biotechnology and pharmaceutical company headquartered in Pittsburgh, Pennsylvania, focused on developing novel cancer therapies and drug pipelines.
MetasTx Inc. is a biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on creating novel therapeutics to treat diseases.
DeuterOncology is a clinical-stage drug development company that designs and develops deuterated MET kinase inhibitors as targeted therapies for lung cancer and other advanced solid tumors. Its lead product, DO-2, is a selective, brain-penetrant MET kinase inhibitor intended to improve tolerability and reduce toxicity compared to existing treatments.
Phenomic AI Inc. is a biotechnology company developing novel antibody-based therapies directed against the tumor stroma to improve patient outcomes.
Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.
Surface Oncology is a clinical-stage biotechnology company focused on developing immunotherapies that target the tumor microenvironment and enhance anti-tumor immune responses. Its programs are intended for cancer patients and are developed for use by oncology physicians and healthcare systems, with potential pharmaceutical partnerships.
Get Duo Oncology Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Duo Oncology Inc. in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access